What we do Speciality Medicines Limited markets and distributes specialty pharmaceuticals used to treat complex chronic diseases, including oncology and rare conditions, across 35 countries. |
Founded in 2,021 |
Market share Strong presence in specialty pharmaceuticals with a broad international footprint over 35 countries. |
Problem solved Providing advanced, high-cost medications for complex chronic and rare diseases needing sophisticated therapies and handling. |
Top clients or who we serve B2B focus serving overseas distributors, government health ministries, and private and government hospitals. |
Key management - |
Our journey and innovations Incorporated in 2021, converted to Public Limited in 2024, IPO issued 2.35 million shares in 2026, growing revenue and profit steadily. |
Where we operate Domestic India and export markets spanning 35 countries worldwide. |
Top products or what we offer Specialty pharmaceutical formulations including capsules, injections, creams, eye drops, inhalers targeting oncology, immunology, and neurology. |
Top brands - |
Raw materials needed Pharmaceutical raw materials for specialty drug formulations including biologics and advanced molecules. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue primarily recurring from ongoing sales and distribution contracts of specialty pharmaceuticals. |
Our industry position Emerging player with expanding international presence in specialty pharma distribution sector. |
Financial highlights FY2022-23 revenue ₹58.27 crore with net profit ₹8.61 crore, indicating profitable growth in early years. |
Geographical revenue split Exports contribute roughly 69% revenue, domestic sales 31%, reflecting strong international demand. |
Order book - |
Whats driving growth Rising demand for complex specialty medicines internationally and strategic partnerships with overseas distributors. |
Our future plans Anticipate organic growth post-IPO with increased distribution capacity and expanded therapeutic portfolio. |
Our green promise - |
Our people and values Committed to compliance, ethical distribution and maintaining a harassment-free workplace environment. |
Key challenges ahead Managing supply chain complexities and high-cost therapies in competitive specialty pharmaceutical markets. |
Interesting facts The company transitioned from private to public and issued equity through IPO within five years of incorporation. |
Risks and strategy Focus on risk management frameworks addressing business and non-business risks, ensuring regulatory compliance. |
